PMID: 7539854Jul 1, 1995Paper

Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study

The Journal of Urology
J Y GillenwaterN Dias

Abstract

A total of 248 hypertensive patients 45 years old or older with benign prostatic hyperplasia (BPH) was included in this 16-week, multicenter, double-blind, placebo-controlled, parallel-group dose-response study. Doxazosin, a selective alpha 1-adrenoceptor antagonist, produced a significant increase in maximum urinary flow rate (2.3 to 3.6 ml. per second) at doses of 4 mg., 8 mg. and 12 mg., and in average flow rate (8 mg. and 12 mg.) compared with placebo. The increase in maximum flow rate was significant with doxazosin versus placebo within 1 week of initiating double-blind therapy. Doxazosin compared to placebo significantly decreased patient-assessed total, obstructive and irritative BPH symptoms. Blood pressure was significantly lower with all doxazosin doses compared with placebo. Adverse events, primarily mild to moderate in severity, were reported in 48% of patients on doxazosin and 35% on placebo. Our results strongly support the use of doxazosin as a nonoperative therapeutic alternative in the management of uncomplicated BPH. Doxazosin would also be particularly useful in the management of patients who have BPH and hypertension.

References

Aug 1, 1976·British Journal of Urology·M CaineS Perlberg
Nov 1, 1990·Journal of Oral Rehabilitation·S J DoneganG J Ziebert
Jan 1, 1986·Virchows Archiv. A, Pathological Anatomy and Histopathology·P ChastonayD Gardiol
Aug 1, 1987·British Journal of Urology·R S KirbyE J Milroy
May 29, 1987·The American Journal of Cardiology·K Hayduk
May 29, 1987·The American Journal of Cardiology·J Rosenthal
May 29, 1987·The American Journal of Cardiology·H L ElliottJ L Reid
Oct 1, 1982·British Journal of Urology·P H AbramsR G Choa
Nov 1, 1994·British Journal of Urology·C R ChappleI Marshall
Jan 1, 1993·Scandinavian Journal of Urology and Nephrology·M M ChristensenS E Husted

❮ Previous
Next ❯

Citations

Jul 14, 2006·Analytical and Bioanalytical Chemistry·Osama Y Al-DirbashiMohamed S Rashed
Apr 30, 2013·Journal of Computer-aided Molecular Design·Tony NgoRenate Griffith
Aug 1, 2002·Current Urology Reports·Kevin T McVary
Jul 21, 2004·Current Urology Reports·Jaspreet S Sandhu, Alexis E Te
Mar 27, 1999·Urology·A ZiadaE D Crawford
Jan 28, 1998·Clinical Therapeutics·R Guthrie
Feb 15, 2001·The Journal of Urology·S P Marinkovic, G Badlani
Nov 24, 1998·Journal of Clinical Pharmacology·V VashiK Phillips
Dec 1, 2007·Clinical Interventions in Aging·Timothy J Wilt, Roderick MacDonald
Nov 26, 2009·Patient Preference and Adherence·Jaspreet S Sandhu
Mar 25, 2008·Therapeutics and Clinical Risk Management·Angelo J Cambio, Christopher P Evans
Apr 20, 2014·Indian Journal of Urology : IJU : Journal of the Urological Society of India·Nadir I OsmanChristopher R Chapple
Aug 13, 2003·The Journal of Urology·Robert R KesterHong Kim
Jul 29, 2003·Current Urology Reports·Chris M Gonzalez, Kevin T McVary
Jun 15, 2007·Expert Opinion on Pharmacotherapy·Jeetesh BhardwaRoger Kirby
Jun 11, 1998·Mayo Clinic Proceedings·M M Lieber

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.